Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
Janssen (Belgium) · Astellas Pharma (Japan) · +12 more institutions
Abstract
Purpose Retrospective studies suggest that metastasis-directed therapy (MDT) for oligorecurrent prostate cancer (PCa) improves progression-free survival. We aimed to assess the benefit of MDT in a randomized phase II trial. Patients and Methods In this multicenter, randomized, phase II study, patients with asymptomatic PCa were eligible if they had had a biochemical recurrence after primary PCa treatment with curative intent, three or fewer extracranial metastatic lesions on choline positron emission tomography-computed tomography, and serum testosterone levels > 50 ng/mL. Patients were randomly assigned (1:1) to either surveillance or MDT of all detected lesions (surgery or stereotactic body radiotherapy).…
Citation impact
- FWCI
- 88.20
- Percentile
- 100%
- References
- 28
Authors
18- POPiet OstCorresponding
Janssen (Belgium), Astellas Pharma (Japan), Bayer (United States), Ipsen (France), Ferring Pharmaceuticals (Switzerland), Ghent University Hospital, Sanofi (France), Astellas Pharma (United Kingdom), Janssen (Switzerland), Ipsen (Spain), Ferring Pharmaceuticals (Netherlands), Ipsen (Ireland), Bayer (France), Takeda (Japan)
- DRDries Reynders
Janssen (Belgium), Astellas Pharma (Japan), Bayer (United States), Ipsen (France), Ferring Pharmaceuticals (Switzerland), Ghent University Hospital, Sanofi (France), Astellas Pharma (United Kingdom), Janssen (Switzerland), Ipsen (Spain), Ferring Pharmaceuticals (Netherlands), Ipsen (Ireland), Bayer (France), Takeda (Japan)
- KDKarel Decaestecker
Janssen (Belgium), Astellas Pharma (Japan), Bayer (United States), Ipsen (France), Ferring Pharmaceuticals (Switzerland), Ghent University Hospital, Sanofi (France), Astellas Pharma (United Kingdom), Janssen (Switzerland), Ipsen (Spain), Ferring Pharmaceuticals (Netherlands), Ipsen (Ireland), Bayer (France), Takeda (Japan)
- VFValérie Fonteyne
Janssen (Belgium), Astellas Pharma (Japan), Bayer (United States), Ipsen (France), Ferring Pharmaceuticals (Switzerland), Ghent University Hospital, Sanofi (France), Astellas Pharma (United Kingdom), Janssen (Switzerland), Ipsen (Spain), Ferring Pharmaceuticals (Netherlands), Ipsen (Ireland), Bayer (France), Takeda (Japan)
- NLNicolaas Lumen
Janssen (Belgium), Astellas Pharma (Japan), Bayer (United States), Ipsen (France), Ferring Pharmaceuticals (Switzerland), Ghent University Hospital, Sanofi (France), Astellas Pharma (United Kingdom), Janssen (Switzerland), Ipsen (Spain), Ferring Pharmaceuticals (Netherlands), Ipsen (Ireland), Bayer (France), Takeda (Japan)
Topics & keywords
- Medicine
- Interquartile range
- Prostate cancer
- Androgen deprivation therapy
- Hazard ratio
- Clinical endpoint
- Biochemical recurrence
- Radiation therapy